UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   Form 10-QSB


      X    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
      EXCHANGE ACT OF 1934

               For the quarterly period ended September 30, 2005


      _    TRANSITION  REPORT  UNDER  SECTION  13 OR  15(d)  OF THE  SECURITIES
           EXCHANGE ACT OF 1934
                     For the transition period from           to
                        Commission File Number 000-24541

                         CORGENIX MEDICAL CORPORATION
                (Name of Small Business Issuer in its Charter)


              Nevada                           93-1223466
  (State or other jurisdiction of    (I.R.S. Employer Identification
  incorporation or organization)                  No.)


                12061 Tejon Street, Westminster, Colorado 80234

         (Address of principal executive offices, including zip code)

                                 (303) 457-4345

               (Issuer's telephone number, including area code)

      (Former  name,  former  address and former  fiscal year, if changed since
      last report)

Check  whether  the  issuer:  (1) filed  all  reports  required  to be filed by
Section  13 or 15(d) of the  Exchange  Act  during  the past 12 months  (or for
such shorter  period that the  registrant  was required to file such  reports),
and  (2)  has  been  subject  to  such  filing  requirements  for  the  past 90
days.     Yes X   No  ___
              -

The number of shares of Common Stock outstanding was 9,041,061 as of November
10, 2005.

Transitional Small Business Disclosure Format.     Yes _   No X
                                                              -

<PAGE>





                          CORGENIX MEDICAL CORPORATION


                               September 30, 2005





                                TABLE OF CONTENTS


                                                                       Page


                                     Part I


                              Financial Information


      Item 1.   Consolidated Financial Statements                       3


      Item 2.   Management's Discussion and Analysis or Plan of
                Operation                                              12



      Item 3.   Controls and Procedures                                19




                                     Part II


                                Other Information


      Item 1.   Legal Proceedings                                      24


      Item 2.   Changes in Securities and Use of Proceeds              24


      Item 3.   Defaults Upon Senior Securities                        24


      Item 4.   Submission of Matters to a Vote of Security Holders    24


      Item 5.   Other Information                                      24


      Item 6.   Exhibits and Reports on Form 8-K                       24


      Certifications                                                   27




<PAGE>


                                     PART I
                   Item 1. Consolidated Financial Statements
                          CORGENIX MEDICAL CORPORATION
                                AND SUBSIDIARIES
Consolidated Balance Sheets
-------------------------------------------------------------------------------


                                     September 30,  2005     June 30, 2005
                                       (Unaudited)
-------------------------------------------------------------------------------
                Assets
Current assets:
  Cash and cash equivalents             $1,103,167              $1,281,965
  Accounts receivable, less allowance for
      doubtful accounts of  $30,410 and
      $13,410                              969,458                 887,645
  Inventories                            1,257,222               1,215,787
  Prepaid expenses                          46,656                  51,842
                                       -----------------------------------------
                  Total current assets   3,376,503               3,437,239
Equipment:
  Capitalized software costs               122,855                 122,855
  Machinery and laboratory equipment       656,401                 639,692
  Furniture, fixtures, leaseholds  &
      office equipment                     523,045                 523,762
                                       -----------------------------------------
                                         1,302,301               1,286,309

  Accumulated depreciation and
amortization                            (1,056,345)             (1,028,103)
                                        ----------------------------------------
  Net equipment                            245,956                 258,206
                                        ---------------------------------------
Intangible assets:
 Patents, net of accumulated
       amortization of  $1,112,594  and
       $1,093,970                           4,950                   23,574
 License                                   18,275                   18,275
                                        ---------------------------------------
                                           23,225                   41,849
Other assets:
  Deferred financing costs net of amortization of
       $119,574 and $39,440               848,727                  907,095
  Restricted cash                         250,000                  250,000
  Due from officer                         12,000                   12,000
  Other assets                             83,421                   86,105
                                        ---------------------------------------
               Total assets             $4,839,832              $4,992,494
                                        =======================================

                 Liabilities and Stockholders' Equity
Current liabilities:
  Current portion of  notes payable,
       net of discount                  $  416,860              $   221,176
  Current portion of capital lease
       obligations                          18,360                   22,370
  Accounts payable                         292,699                  453,764
  Accrued payroll and related
       liabilities                         219,284                  218,411
  Accrued interest                             722                      753
  Accrued liabilities                       51,336                  113,293
                                        ---------------------------------------

                Total current liabilities  999,261                1,029,767

Notes payable, excluding current
      portion, net of discount           1,218,718                  980,716
Capital lease obligations, excluding
      current portion                       18,715                   22,754
                                        ---------------------------------------

                  Total liabilities      2,236,694                2,033,237

Redeemable common stock, 880,282 shares
   issued and outstanding, aggregate
   redemption value of $500,000, net of
   redeemable stock subject to redemption
   via payments on related note payable,
   of $250,000 at September 30, 2005
   (note 5)                                250,000                  500,000

Stockholders' equity (deficit):
  Preferred stock, $0.001 par value.
  Authorized 5,000,000 shares, none
  issued or outstanding                       -                         -

Common stock, $0.001 par value.
  Authorized 40,000,000 shares; issued
  and outstanding and 8,587,390 and
  8,172,435 on September 30 and June 30,
  respectively                              7,707                     7,292
Additional paid-in capital              7,984,058                 7,966,172
Accumulated deficit                    (5,625,252)               (5,501,144)
Accumulated other comprehensive income    (13,375)                  (13,063)
                                        ---------------------------------------

      Total stockholders' equity        2,353,138                 2,459,257
                                        ---------------------------------------
Total liabilities and stockholders'
      equity                           $4,839,832               $ 4,992,494
                                        =======================================

See accompanying notes to consolidated financial statements.


<PAGE>


5
4

                          CORGENIX MEDICAL CORPORATION
                                AND SUBSIDIARIES

Consolidated Statements of Operations

-------------------------------------------------------------------------------

                                       Three Months Ended

                                       September 30,    September 30,
                                           2005              2004
                                        (Unaudited)      (Unaudited)
-------------------------------------------------------------------------------


Net sales                              $1,634,953        $1,303,071

Cost of sales                             581,866           557,222
                                         ---------          -------


          Gross profit                  1,053,087           745,849
                                         ---------          -------


Operating expenses:
  Selling and marketing                  380,712           375,938

  Research and development               128,510           156,558

  General and administrative             330,103           299,349
                                       ---------          ---------

  Total expenses                         839,325           831,845
                                       ------------------------------


          Operating  income (loss)       213,762          (85,996)


Interest expense                         337,870          104,203
                                       -----------------------------

Net loss                                (124,108)        (190,199)

Accretion of discount on redeemable
common stock                               --              21,639
                                       -----------------------------


Net loss available to common
stockholders                           $(124,108)       $(211,838)
                                       =============================

 Net loss per common share, basic and
diluted                                $   (0.01)        $ (0.04)


Weighted average shares outstanding,    8,379,052        5,324,818
 basic and diluted                     =============================

          Net loss                     $ (124,108)       $(190,199)


 Other comprehensive loss-foreign
 currency    translation income (loss)       (312)            410
                                       -----------------------------

 Total comprehensive loss              $  (124,420)      $(189,789)

See accompanying notes to consolidated financial statements.




<PAGE>


                          CORGENIX MEDICAL CORPORATION
                                AND SUBSIDIARIES
                 Consolidated Statement of Stockholders' Equity
                  For the three months ended September 30, 2005
                                   (Unaudited)

                 Common                               Accumulated
                 Stock,  Common  Additional              other        Total
                Number  Stock,  paid-in  Accumulated comprehensive stockholders'
                  of     Amount  capital   Deficit       income       equity
                Shares
                  -------------------------------------------------------------
                  -------------------------------------------------------------

Balance at June  8,172,435 $7,292 $7,966,172 $(5,501,144)  $(13,063) $2,459,257
30, 2005

Issuance of common
stock for services  50,717    51    11,350                             11,401

Issuance of common
stock upon exercise 30,000    30     6,870                              6,900
of warrants for cash

Issuance of common
stock upon exercise
of warrants,       334,238    334    (334)                                --
cashless

Foreign currency
translation                                                    (312)      (312)
Net loss                                        (124,108)             (124,108)
                       ---------------------------------------------------------
Balance at September
30, 2005         8,587,390   $7,707 $7,984,058 $(5,625,252)$(13,375) $2,353,138
                ===============================================================
See accompanying
  notes to
  consolidated
  financial
  statements.



<PAGE>







                          CORGENIX MEDICAL CORPORATION
                                AND SUBSIDIARIES



Consolidated Statements of Cash Flows
-------------------------------------------------------------------------------

                                                     Three Months Ended
                                               September 30,   September 30,
                                                   2005            2004
                                               ----------------------------

(Unaudited) (Unaudited) Cash flows from operating activities:
  Net loss                                     $(124,108)      $(190,199)
  Adjustments to reconcile net loss to
 net cash provided (used) in operating
 activities:

             Depreciation and amortization         47,389         46,068
             Accretion of discount on
             note payable                         188,686         83,903
             Common stock issued for services      11,401          3,639
             Amortization of deferred
             financing costs                       80,134            --
             Changes in operating assets
             and liabilities:
                  Accounts receivable, net        (88,154)       105,093
                  Inventories                     (42,388)      (128,186)
                  Prepaid expenses and            (14,605)       (12,250)
                  other assets, net
                 Accounts payable                (150,378)       151,885
                 Accrued payroll and
                 related liabilities                1,182         (2,343)
                 Accrued liabilities,
                 including accrued interest       (62,048)       (36,752)
                                               -------------------------------

                    Net cash provided (used)
                    in operating activities      (152,889)        20,858
                                               -------------------------------

Cash flows used by investing activities:
   Additions to equipment                         (16,710)        (6,528)
                                               --------------------------------

Cash flows from financing activities:

  Proceeds upon exercise of warrants                6,900            -
  Payments on notes payable                        (5,000)       (35,614)
  Payments on capital lease obligations            (8,049)       (20,774)
                                               --------------------------------

                      Net cash used by
                      financing activities         (6,149)       (56,388)
                                               --------------------------------

                      Net decrease in cash
                      and cash equivalents       (175,748)       (42,058)

Impact of exchange rate on cash                    (3,050)            58

Cash and cash equivalents at beginning of
period                                          1,281,965        468,954
                                               --------------------------------

Cash and cash equivalents at end of period     $1,103,167       $426,954
                                               --------------------------------


Supplemental cash flow disclosures:

  Cash paid for interest                       $   76,283       $11,443
  Noncash investing and financing
   activities-                                 --------------------------------
        Equipment acquired under capital       $     -          $45,400
        leases
        Conversion of redeemable common        $  250,000       $  --
        stock to note payable
                                               --------------------------------

See accompanying notes to consolidated financial statements.




<PAGE>


                 CORGENIX MEDICAL CORPORATION AND SUBSIDIARIES

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1.    DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

Company Overview


      Corgenix Medical Corporation, which we refer to as Corgenix or the
Company, is engaged in the research, development, manufacture, and marketing of
in vitro (outside the body) diagnostic products for use in disease detection and
prevention. We currently sell 51 diagnostic products on a worldwide basis to
hospitals, clinical testing laboratories, universities, biotechnology and
pharmaceutical companies and research institutions. In the United States and the
United Kingdom, we sell directly to these customers. Elsewhere in the world, we
primarily sell to independent distributors that in turn sell to the
laboratories.

Our corporate headquarters is located in Westminster, Colorado. We have two
wholly owned operating subsidiaries:

o     Corgenix, Inc. (formerly REAADS Medical Products, Inc.), established in
        1990 and located in Westminster, Colorado. Corgenix, Inc. is
        responsible for sales and marketing activities for North America, and
        also executes product development, product support, clinical and
        regulatory affairs, and product manufacturing.

o       Corgenix (UK) Ltd incorporated in the United Kingdom in 1996 (formerly
        REAADS Bio-Medical Products (UK) Limited), and located in Peterborough,
        England. Corgenix UK manages our international sales and marketing
        activities except for distribution in North America, which is under the
        responsibility of Corgenix, Inc.

We continue to use the REAADS trademark and trade name in the sale of products
that we manufacture.

Recent Developments

      On October 15, 2004 the Company and Genesis Bioventures, Inc. (which we
refer to as GBI or Genesis) a biomedical development company focused on the
development of diagnostic tests, signed an amendment to the May 21, 2004 Amended
and Restated Agreement and Plan of Merger (the "Merger Agreement"), extending
the closing date for the proposed merger to on or before February 28, 2005. The
extension was executed in the form of Amendment No. 1 (the "Amendment") to the
Merger Agreement, a copy of which was filed on Form 8-K on October 20, 2004.

      The Amendment, among other changes, allowed the Company to terminate the
Merger Agreement at any time prior to November 30, 2004 if it were not satisfied
with the terms or the progress of the new equity financing. A new equity
financing in an amount of at least $6,000,000 was a condition to the closing of
the Merger pursuant to section 9.13 of the Merger Agreement. On November 30,
2004, the Company and Genesis agreed to extend the date for obtaining the
financing to December 10, 2004. On December 9, 2004, the parties agreed to
extend the date to December 31, 2004, and on December 31, 2004, the parties
agreed to extend the deadline for terminating the Merger Agreement to January
15, 2005. These extensions are documented as Amendments No. 2, 3 and 4 to the
Merger Agreement. Management of Corgenix believed that, given the delays
experienced during the holiday season, and given the timing delays that are
often associated with seeking funds in overseas markets, it was appropriate and
in the best interests of the Company to allow Genesis additional time to pursue
the new equity financing.

      As previously disclosed, on January 14, 2005 Corgenix terminated the
Merger Agreement with Genesis due to the lack of progress towards the completion
of the $6.0 million merger-related financing and the expiration of key dates
within the Merger Agreement (as amended).

      The Company entered into agreements on May 19, 2005, for a private
placement financing with certain institutional and accredited investors,
including Truk International Fund, LP, Truk Opportunity Fund, LLC and DCOFI
Master LDC, representing potential gross proceeds to the Company of up to
$5,135,000.

      The private placement included $3,420,000 in aggregate principal amount of
Secured Convertible Term Notes due 2008, of which $2,420,000 was funded at
closing. The remaining $1,000,000 is issuable by the Company upon the
satisfaction of certain conditions contained in the transaction agreements. Of
the amount funded at closing, $250,000 is held in a restricted cash account.
However, that amount will be released if the Company's common stock trades a
minimum daily value of $25,000 at an average closing price per share of $0.40 or
greater for 22 consecutive trading days. As of November 7, 2005, this event had
not yet occurred. The private placement also provided for up to $1,500,000 in
subsequent debt funding through an additional investment right exercisable by
the investors, in their sole discretion, for up to 270 days following the
closing. We also sold 860,000 shares of restricted common stock, at $0.25 per
share. Together with the notes and common stock, we also issued warrants to
acquire approximately 7,700,000 shares of the Company's common stock, 6,840,000
of which were issued to the Debt Investors and 860,000 of which were issued to
the purchasers of our common stock. On June 23, 2005, as the final part of this
financing, an additional 400,000 shares of restricted common stock and 400,000
warrants were issued under identical terms as noted above.

      The interest rate on the Secured Convertible Term Notes is the greater of
(i) prime rate plus 3% or (ii) 12%, except for the portion of the note proceeds
that is held in the restricted cash account, which amount accrues interest at
the prime rate. However, (i) if the Company has registered the shares of common
stock underlying the term notes and the warrants, and that registration is
declared effective, and (ii) the market price of the common stock for the five
consecutive trading days preceding the last business day of each month exceeds
the conversion price (as adjusted) by 25%, then the interest rate for the next
calendar month is reduced by 25 basis points for each incremental 25% increase
in the market price above the fixed conversion price. As of the date of this
filing, the shares underlying the notes and warrants have been registered.

      The principal amount of each Secured Convertible Term Note is divided into
three categories - Amortizing Principal Amount, Non-Restricted Non-Amortizing
Principal Amount, and Restricted Non-Amortizing Principal Amount. Amortizing
payments of the Amortizing Principal Amount begin on November 1, 2005 and such
payments are due on the first day of each month until the amount is paid in
full. The Non-Amortizing Principal Amount and the Restricted Non-Amortizing
Principal Amount, together with any unpaid Amortizing Principal Amount and
accrued but unpaid interest or fees, are due on May 19, 2008 (the maturity
date), unless sooner paid. Interest payments on all three amounts began June 1,
2005, and such interest payments are due on the first day of each subsequent
month.

      The Secured Convertible Term Notes may be prepaid, but any prepayment must
be 125% of the portion of the principal amount to be prepaid, together with
accrued but unpaid interest thereon and any other sums due. The holders of the
Secured Convertible Term Notes may accelerate all sums of principal, interest
and other fees then remaining unpaid upon the occurrence of an event of default,
as defined in the form of note, beyond any applicable grace period. In the event
of such acceleration, the amount due and owing the holder shall be 125% of the
outstanding principal amount (plus accrued and unpaid interest and fees, if
any). As part of the financing terms, a blanket lien now covers all of the
Company's assets.

      The number of shares of common stock to be issued upon conversion of a
Secured Convertible Term Note is determined by dividing that portion of the
principal amount, interest and fees to be converted by the then applicable
conversion price, which is initially set at $0.30. The conversion price may be
adjusted to account for certain events, such as stock splits, combinations,
dividends and share issuances below the then current conversion price.

      The conversion right of the Secured Convertible Term Notes contains a
limitation. The holder will not convert an amount that would be convertible into
that number of conversion shares which, when added to the number of shares of
common stock beneficially owned by such holder or issuable if the holder
exercised one or more of its warrants, immediately prior to conversion, would
exceed 4.99% of the Company's issued and outstanding common stock.

      As noted above, the Company also issued warrants to acquire approximately
7,700,000 shares (exclusive of placement agent warrants) of the Company's common
stock. The warrants are exercisable for seven years from the date of issuance at
an exercise price of $0.23 per share. The exercise price is also subject to
adjustment upon the occurrence of certain specified events, including issuance
of additional shares of common stock or subdivision or combining of shares of
common stock.

      The private placement also included a registration rights agreement
pursuant to which the Company agreed to file a registration statement on Form
SB-2, covering the shares of common stock issuable upon the exercise of the
warrants issued to the debt investors or the conversion of the Secured
Convertible Term Notes. The registration statement was declared effective on
August 2, 2005.

      Certain officers, directors and significant shareholders entered into
lockup agreements whereby they agreed not to sell, offer, contract or grant any
option to sell, pledge, transfer, establish an open "put equivalent position" or
otherwise dispose of their shares of the Company's common stock, or any
securities exchangeable or convertible into common stock, for a period of six
months from the effective date of the initial registration statement covering
shares of Common Stock which may be acquired by the investors in connection with
the transaction. The lockup agreements will expire on February 2, 2006.

      With the private placement described above, the Company has refinanced
$1,016,196 of existing debt, including loans from Vectra Bank, SBA and Genesis
Bioventures, Inc., which are described immediately below, and plans to use the
balance of the net proceeds, after transaction fees and expenses, for key
strategic initiatives, working capital and other general corporate purposes.

      On March 24, 2004, Genesis advanced $500,000 to Corgenix, which is
represented by a promissory note that we refer to as the Bridge Note. As of May
19, 2005, the Company owed $470,000 on the Bridge Note, less offsets of
approximately $50,000. As a result of the termination of the Genesis Merger
Agreement, the note converted to a fixed two-year term note bearing interest at
the prime rate in effect as of the date of termination of the Merger Agreement,
or 5.25%. The note was to be fully-amortized over four semi-annual payments of
principal and accrued interest; the note was also convertible, at the election
of Genesis, into Corgenix common stock at a conversion price of $.568 per share.

      The market value of the Company's stock had increased from the date of the
letter of intent to the date the Bridge Note was executed, resulting in a
beneficial conversion feature that was credited to equity, and an equal amount
was recognized as interest expense over the term of the Bridge Note, using the
effective interest method. As stated above, as part of the Private Placement,
the Bridge Note was purchased from Genesis by the Private Placement investors,
and the net amount owing of $420,000 became part of the $2,420,000 funded at
closing and owing on the Secured Convertible Term Notes. As a consequence of the
purchase by the Private Placement investors of the Genesis note, the unaccreted
discount on the Bridge Note was written off and charged to Loss on
Extinguishment of Debt.

      Immediately prior to the private placement, the Company had a variable
rate note payable to a bank in the amount of approximately $295,000 which had
been due in full at January 31, 2005. This variable rate note payable was paid
in full out of the proceeds of the private placement.

      Our Business

           Introduction

      Our business includes the research, development, manufacture, and
marketing of in vitro diagnostic products for use in disease detection and
prevention. We sell 51 diagnostic products on a worldwide basis to hospitals,
clinical testing laboratories, universities, biotechnology and pharmaceutical
companies and research institutions. We have developed and we manufacture most
of our products at our Colorado facility, and we purchase what we refer to as OM
Products from other healthcare manufacturers for resale by us. All of these
products are used in clinical laboratories for the diagnosis and/or monitoring
of three important areas of health care:

o       Autoimmune disease (diseases in which an individual creates antibodies
        to one's self, for example systemic lupus erythematosus ("SLE") and
        rheumatoid arthritis ("RA");

o       Vascular disease (diseases associated with certain types of thrombosis
        or clot formation, for example antiphospholipid syndrome, deep vein
        thrombosis, stroke and coronary occlusion); and

o Liver diseases (fibrosis, cirrhosis and transplanted organ rejection).

      In addition to our current products, we are actively developing new
laboratory tests in other important diagnostic testing areas. See "-- Other
Strategic Relationships." We manufacture and market to clinical laboratories and
other testing sites worldwide. Our customers include large and emerging health
care companies such as Instrumentation Laboratories, Helena Laboratories and
Diagnostic Grifols, S.A.

      Most of our products are based on our patented and proprietary application
of Enzyme Linked ImmunoSorbent Assay or ELISA technology, a clinical testing
methodology commonly used worldwide. Most of our current products are based on
this platform technology in a delivery format convenient for clinical testing
laboratories. The delivery format, which is referred to as "Microplate," allows
the testing of up to 96 samples per plate, and is one of the most commonly used
formats, employing conventional testing equipment found in virtually all
clinical laboratories. The availability and broad acceptance of ELISA Microplate
products reduces entry barriers worldwide for our new products that employ this
technology and delivery format. Our products are sold as "test kits" that
include all of the materials required to perform the test, except for routine
laboratory chemicals and instrumentation. A test using ELISA technology involves
a series of reagent additions into the Microplate, triggering a complex
immunological reaction in which a resulting color occurs. The amount of color
developed in the final step of the test is directly proportional to the amount
of the specific marker being tested for in the patient or unknown sample. The
amount of color is measured and the results calculated using routine laboratory
instrumentation. Our technology specifies a process by which biological
materials are attached to the fixed surface of a diagnostic test platform.
Products developed using this unique attachment method typically demonstrate a
more uniform and stable molecular configuration, providing a longer average
shelf life, increased accuracy and superior specificity than the products of our
competitors.

      Some of the OM products which we obtain from other manufacturers and sell
through our distribution network utilize technologies other than our patented
and proprietary ELISA technology.

      Our diagnostic tests are intended to aid in the identification of the
causes of illness and disease, enabling a physician to select appropriate
patient therapy.

      Internally and through collaborative arrangements, we are developing
additional products that are intended to broaden the range of applications for
our existing products and to result in the introduction of new products.

      Since 1990, our sales force and distribution partners have sold over 12
million tests worldwide under the REAADS and Corgenix labels, as well as
products sold under other manufacturers' labels, referred to as OEM products. An
integral part of our strategy is to work with corporate partners to develop
market opportunities and access important resources. We believe that our
relationships with current and potential partners will enable us to enhance our
menu of diagnostic products and accelerate our ability to penetrate the
worldwide markets for new products.

      We currently use the REAADS and Corgenix trademarks and trade names in the
sale of the products which we manufacture. These products constitute the
majority of our product sales.

2. EARNINGS PER SHARE Basic earnings (loss) per share is computed by dividing
net loss attributable to common stockholders by the weighted average number of
common shares outstanding. Diluted earnings (loss) per share is computed by
dividing net loss attributable to common stockholders by the weighted average
number of common shares outstanding increased for potentially dilutive common
shares outstanding during the period. The dilutive effect of stock options and
their equivalents is calculated using the treasury stock method. Stock options
to acquire 25,000 shares were granted in the most recent quarter. No stock
options were granted in the quarter ended September 30, 2004. Options, warrants
and the rights under convertible debt to purchase common stock totaling
12,773,963 and 1,407,100 shares for fiscal quarters ended September 30, 2005 and
2004 respectively, are not included in the calculation of weighted average
common shares-diluted below as their effect is anti-dilutive. Redeemable common
stock is included in the common shares outstanding for purposes of calculating
net income (loss) per share.




The components of basic and diluted loss per share as follows:

                                         3 months ended    3 months ended
                                          September 30,     September 30,
                                             2005                2004
                                         -------------------------------------

Net loss attributable to common            $(124,108)         $(211,838)
  stockholders

     Common and common equivalent shares outstanding:
   Historical common shares outstanding
    at beginning of period                 8,172,435          5,321,319
   Weighted average common equivalent
    shares issued during period              206,617              3,499
                                         --------------------------------------

  Weighted average common shares -
    basic and diluted                      8,379,052          5,324,818
                                         ======================================

 Net loss per share - basic and diluted   $     (.01)         $   (.04)
                                         ======================================

3. INCOME TAXES

A valuation allowance was provided for deferred tax assets, as
the Company is unable to conclude under relevant accounting standards that it is
more likely than not that deferred tax assets will be realizable.

4. SEGMENT INFORMATION

The Company has two segments of business: North American and
International operations. North American operations transacts all sales in North
America (US, Canada and Mexico). International operations transacts all other
sales. The following table sets forth selected financial data for these segments
for the three-month periods ended September 30, 2005 and 2004.


                                        Three Months Ended September 30

                       North America       International           Total

Net sales 2005         $1,245,518           $ 389,435          $  1,634,953
          2004         $  974,275           $ 328,796          $  1,303,071
                     ----------------------------------------------------------


Net income/(loss)
          2005       $ (287,983)            $163,875           $ (124,108)
          2004       $ (258,028)            $ 67,829           $ (190,199)
                     ----------------------------------------------------------

Depreciation and
amortization
          2005       $   46,954             $    435           $   47,389
          2004       $   45,504             $    564           $   46,068
                     ----------------------------------------------------------

Interest expense, net
          2005       $  335,990             $   1,880          $  337,870
          2004       $  103,189             $   1,014          $  104,203
                     ----------------------------------------------------------


Segment assets
September 30, 2005   $4,332,216             $ 507,616          $ 4,839,832
June 30, 2005        $2,526,501             $ 319,524          $2,846,025
                     ----------------------------------------------------------







5.    REDEEMABLE COMMON STOCK

      On July 1, 2002, as part of the Medical & Biological Laboratories Co.,
Ltd. (MBL) Agreement, MBL purchased shares of the Company's common stock for
$500,000, which, at the time, MBL was permitted to put to the Company for
repurchase at the same price if a previously existing distribution agreement
with RhiGene, Inc. were terminated. For no additional consideration, MBL was
also issued warrants to purchase an additional 880,282 shares of Common Stock at
a price of $.568 per share, which is equal to an aggregate amount of $500,000.
These warrants originally were set to expire on July 3, 2007 and may be
exercised in whole or in part at any time prior to their expiration. The
estimated fair value of the warrant upon issuance was calculated as $401,809
using the Black-Scholes option-pricing model with the following assumptions: no
expected dividend yield, 143% volatility, risk free interest rate of 4.2% and an
expected life of five years. The gross proceeds of $500,000 were allocated
$277,221 to redeemable common stock and $222,779 to the related warrants based
on the relative fair values of the respective instruments to the fair value of
the aggregate transaction. Issuance costs and the discount attributed to the
redeemable common stock upon issuance were accreted over the 33-month period to
the first date whereupon the put option may be exercised, which was the
expiration date of the distribution agreement between the Company and RhiGene,
Inc. (March 31, 2005). Furthermore, pursuant to the agreement with MBL, as long
as MBL holds at least 50% of the common stock purchased under the MBL agreement,
MBL must give its written consent with respect to the payment of any dividend,
the repurchase of any of the Company's equity securities, the liquidation or
dissolution of the Company or the amendment of any provision of the Company's
Articles of Incorporation or Bylaws which would adversely affect the rights of
MBL under the stock purchase transaction documents. MBL was granted standard
anti-dilution rights with respect to stock issuances not registered under the
Securities Act and received standard piggyback registration rights along with
certain demand registration rights. MBL did not elect to register its redeemable
shares in the SB -2 registration statement filed by the Company on June 25, 2005
and declared effective on August 2, 2005.

      On March 31, 2005 our distribution agreement with RhiGene expired, and the
Company signed a new distribution and OEM Supply Agreement with MBL
International, Inc. ("MBLI"), a wholly owned subsidiary of MBL, which grants the
Company non-exclusive rights to distribute MBL's complete diagnostic line of
autoimmune testing products in the United States and exclusive distribution
rights to the OEM Label products worldwide excluding the United States, Japan,
Korea and Taiwan. In addition, on August 1, 2005 the Company and MBL executed an
Amendment to the Common Stock Purchase Agreement and Common Stock Purchase
Warrant wherein one-half or 440,141of the original redeemable shares are to be
exchanged over time for a three-year promissory note payable with interest at
prime (6.75% as of September 30, 2005) plus two percent with payments commencing
before September 1, 2005. The shares exchanged for the promissory note will be
returned to the Company quarterly on a pro rata basis as payments are made on
the promissory note. The remaining 440,141 shares must be redeemable by the
Company at $0.568 per share as of August 1, 2008 for any shares still owned at
that time by MBL and only to the extent that MBL has not realized at least
$250,000 in gross proceeds upon the sales of its redeemable shares in the open
market for the time period August 1, 2005 through August 30, 2008. Finally, the
warrants originally issued to MBL to purchase 880,282 shares have been extended
to August 31, 2008 and re-priced from $0.568 per share to $0.40 per share.



6.  STOCK-BASED COMPENSATION


      The Company accounts for its stock plans in accordance with the provisions
of Accounting Principles Board (APB) Opinion No. 25, Accounting for Stock Issued
to Employees, SFAS No.148, Accounting for Stock-Based Compensation-Transition
and Disclosure, and related interpretations. As such, compensation expense is
recorded on the date of grant only if the current market price of the underlying
stock exceeds the exercise price. SFAS No. 123, Accounting for Stock-Based
Compensation, permits entities to recognize as expense over the vesting period
the fair value of all stock-based awards on the date of grant. Alternatively,
SFAS No. 123 also allows entities to continue to apply the provisions of APB
Opinion No. 25 and provide pro forma net loss disclosures for employee stock
option grants as if the fair-value-based method defined in SFAS No. 123 had been
applied. The Company has elected to continue to apply the provisions of APB
Opinion No. 25 and provide the pro forma disclosures required by SFAS No. 123.

      Had the Company determined compensation cost based on the fair value at
the date of grant for its stock options under SFAS No. 123, the Company's net
income (loss) would have been increased to the pro forma amounts indicated as
follows:


                                      Three Months       Three Months
                                         Ended              Ended
                                     September 30,     September 30,
                                         2005                2004
                                   ----------------------------------
                                   ----------------------------------

  Net  loss   attributable   to
    common    shareholders   as     $    (124,108)    $   (190,199)
    reported

  Deduct   total    stock-based
    employee       compensation
    expense   determined  under           (16,977)    $    (10,679)
    fair-value  method  for all
    awards, net of tax

  Pro forma net loss                $    (141,085)    $   (200,878)

  Net loss per share, basic
    and diluted as reported         $       (0.01)    $      (0.04)

  Net loss per share, basic
    and diluted pro forma           $       (0.02)    $      (0.04)

      As of September 30, 2005, there were also 11,409,086 outstanding warrants
issued to institutional investors, consultants and employees outstanding and
exercisable ranging in prices from $.23 to $1.25 per share with a weighted
average exercise price of $.26 per share. Fair value was determined using the
Black Scholes option - pricing model with the following assumptions: no expected
dividends, volatility of 159.9% in fiscal 2005, risk-free interest rate of 3.30
% in fiscal 2005 and expected lives of seven years.

7.  RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

      FAS 123R Disclosure. In December 2004, the FASB issued SFAS No. 123(R),
Share-Based Payment, which is a revision of SFAS No. 123, Accounting for
Stock-Based Compensation. SFAS No. 123(R) will be effective for the Company
beginning January 1, 2006, and supersedes APB Opinion No. 25, Accounting for
Stock Issued to Employees, and amends SFAS No. 95, Statement of Cash Flows. SFAS
No. 123(R) requires all share-based payments to employees, including grants of
employee stock options, to be recognized in the income statement based on their
fair values. Pro-forma disclosure is no longer an alternative. The Company does
not expect the adoption of FAS 123(R) will have a material impact on the
Company's financial statements.

      FAS 154 Disclosure. In June 2005, the FASB issued SFAS No. 154, Accounting
Changes and Error Corrections, a replacement of APB Opinion No. 20 and SFAS No.
3. The statement applies to all voluntary changes in accounting principles, and
changes the requirements for accounting for and reporting of a change in
accounting principle. The Company does not believe the adoption of SFAS No. 154
will have a material impact on the Company's financial statements.












<page>



8.  NOTES PAYABLE

      Notes payable consist of the following at September 30, 2005 and June 30,
2005:



                                              September 30,     June 30,
                                                 2005             2005
                                              -------------------------------


    Secured, amortizing convertible term note payable to
    institutional investors, net of discount of
    $1,029,422, with interest at the
    greater of 12% or prime plus 3%
    (12% as of September 30, 2005),
    interest only from June 1, 2005 through
    October 1, 2005 and then due in monthly
    installments of $55,667 plus interest
    through May 19, 2008, collateralized by
    commercial security agreements and a
    partial guaranty by an officer of the
    company. See discussion of terms below.    $ 640,578      451,892

    Secured, non-amortizing convertible term note
    payable to institutional investors, with
    interest at the greater of 12% or prime plus
    3% (12% as of June 30, 2005), interest,
    interest only payments commencing June
    1, 2005 until  May 19, 2008,
    collaterialized by commercial security
    agreements. See discussion of terms
    below.                                       500,000      500,000

    Secured, restricted, non-amortizing
    convertible term note payable to institutional
    investors, with interest at prime (6% at June 30,
    2005), interest only payments commencing
    June 1, 2005 until the earlier of
    May 19, 2008 or the date the proceeds to the
    company are no longer restricted,
    collateralized by commercial security
    agreements. See discussion of terms below.   250,000      250,000

    Note payable, unsecured, to redeemable
    common stockholders, with interest at
    prime plus 2.0% (8.75% at September 30, 2005)
    due in monthly installments with principal
    payments ranging from $5,000 to $10,000
    plus interest through August 2008.           245,000        --

                                              ---------------------------------

                                               1,635,578     1,201,892
    Current portion,  net of current
      portion of discount                       (416,860)     (221,176)
                                              ---------------------------------

     Notes payable, excluding current portion  $1,218,718     980,716
                                              =================================

        Certain of the notes payable restrict the payment of dividends on the
Company's common stock. As described in note (1), Genesis advanced $500,000 to
the Company under the Bridge Note. Interest accrued on the principal balance of
the Bridge Note from January 14, 2005, the date the planned merger was
terminated until May 19, 2005, the date the Bridge Note was purchased as part of
the Private Placement Financing. The market value of the Company's stock was in
excess of the potential conversion price at the date the note was executed,
resulting in a beneficial conversion feature of approximately $660,000. As
required by Emerging Issues Task Force Bulletins 98-5, "Accounting for
Convertible Securities with Beneficial Conversion Features of Contingently
Adjustable Conversion Ratios" and 00-27, "Application of Issue 98-5 to Certain
Convertible Instruments", the entire proceeds of the Bridge Note were credited
to additional paid-in capital. The Bridge Note was recorded net of a $500,000
discount, which was being accreted to interest expense over the potential term
of the Bridge Note.

      On May 19, 2005, we entered into a series of agreements with Truk
Opportunity Fund, LLC, a Delaware limited liability company, Truk International
Fund, LP, a Cayman Islands company, and DCOFI Master LDC, a Cayman Islands
company, which has subsequently changed its name to CAMOFI Master LDC, a Cayman
Islands company (together, the "Debt Investors"), pursuant to which we issued
secured convertible term notes in the aggregate principal amount of $2,420,000
due May 19, 2008, together with 6,840,000 common stock purchase warrants. In
this financing, $250,000 is held in a restricted cash account. However, that
amount will be released if the Company's common stock trades a minimum daily
value of $25,000 at an average closing price per share of $0.40 or greater for
22 consecutive trading days. As of November 7, 2005, this event had not yet
occurred. We also entered into a registration rights agreement whereby, among
other things, we agreed to file a registration statement, with the SEC, to
register the resale of the shares of common stock that we will issue upon
exercise of the warrants held by the Debt Investors and upon conversion of their
notes. We agreed to keep the registration statement effective until the date
when all of the shares registered could be sold or the date on which the shares
registered can be sold without registration and without restriction as to the
number of shares that may be sold. The notes are convertible into shares of our
common stock at a conversion rate of $0.30 per share and the exercise price of
the warrants is $0.23 per share, each subject to adjustments as specified in the
applicable agreements. The warrants may be exercised until May 19, 2012. The
estimated relative fair value of the warrants upon issuance of the convertible
notes payable was calculated as $935,482 using the Black-Scholes option-pricing
model with the following assumptions: no expected dividend yield, volatility of
159.9%, risk-free interest rate of 3.30% and an expected life of seven years.
The gross proceeds of the secured convertible term notes of $2,420,000 were
allocated $1,484,518 to notes payable and $935,482 to the related warrants. The
market value of the Company's common stock was in excess of the effective
conversion price after allocation, resulting in a beneficial conversion feature
(discount) of $370,816. As required by Accounting Principles Board Opinion 14,
"Accounting for Convertible Debt and Debt Issued with Stock Purchase Warrants",
Emerging Issues Task Force Bulletins 98-5, "Accounting for Convertible
Securities with Beneficial Conversion Features of Contingently. Adjustable
Conversion Ratios" and 00-27, "Application of Issue 98-5 to Certain Convertible
Instruments", the portion of the proceeds equal to the total discount attributed
to both the warrants and the beneficial conversion feature was credited to
additional paid in capital. The convertible debt was recorded net of the
$1,306,298 total discount, which is being accreted to interest expense over the
36-month term of the notes payable.





























<page>


  Item 2.

      CORGENIX MEDICAL CORPORATIONManagement's Discussion and Analysis Of
                 Financial Condition and Results of Operations

      The   following   discussion   should   be   read  in
conjunction with the consolidated financial statements and accompanying notes
included elsewhere herein.
           General

      Since the Company's inception, we have been primarily involved in the
research, development, manufacturing and marketing/distribution of diagnostic
tests for sale to clinical laboratories. We currently market 51 products
covering autoimmune disorders, vascular diseases, infectious diseases and liver
disease. Our products are sold in the United States, the UK and other countries
through our marketing and sales organization that includes direct sales
representatives, contract sales representatives, internationally through an
extensive distributor network, and to several significant OEM partners.

      We manufacture products for inventory based upon expected sales demand,
shipping products to customers, usually within 24 hours of receipt of orders if
in stock. Accordingly, we do not operate with a significant customer order
backlog.

      Except for the fiscal year ending June 30, 1997, we have experienced
revenue growth since our inception, primarily from sales of products and
contract revenues from strategic partners. Contract revenues consist of service
fees from research and development agreements with strategic partners.

      Beginning in fiscal year 1996, we began adding third-party OM licensed
products to our diagnostic product line. Currently we sell 128 products licensed
from or manufactured by third party manufacturers. We expect to expand our
relationships with other companies in the future to gain access to additional
products.

      Although we have experienced growth in revenues every year since 1990,
except for 1997, there can be no assurance that, in the future, we will sustain
revenue growth, current revenue levels, or achieve or maintain profitability.
Our results of operations may fluctuate significantly from period-to-period as
the result of several factors, including: (i) whether and when new products are
successfully developed and introduced, (ii) market acceptance of current or new
products, (iii) seasonal customer demand, (iv) whether and when we receive
research and development payments from strategic partners, (v) changes in
reimbursement policies for the products that we sell, (vi) competitive pressures
on average selling prices for the products that we sell, and (vii) changes in
the mix of products that we sell.

      Recently Issued Accounting Pronouncements

      FAS 123R Disclosure. In December 2004, the FASB issued SFAS No. 123(R),
Share-Based Payment, which is a revision of SFAS No. 123, Accounting for
Stock-Based Compensation. SFAS No. 123(R) will be effective for the Company
beginning January 1, 2006, and supersedes APB Opinion No. 25, Accounting for
Stock Issued to Employees, and amends SFAS No. 95, Statement of Cash Flows. SFAS
No. 123(R) requires all share-based payments to employees, including grants of
employee stock options, to be recognized in the income statement based on their
fair values. Pro-forma disclosure is no longer an alternative. The Company does
not expect the adoption of FAS 123(R) will have a material impact on the
Company's financial statements.

      FAS 154 Disclosure. In June 2005, the FASB issued SFAS No. 154, Accounting
Changes and Error Corrections, a replacement of APB Opinion No. 20 and SFAS No.
3. The statement applies to all voluntary changes in accounting principles, and
changes the requirements for accounting for and reporting of a change in
accounting principle. The Company does not believe the adoption of SFAS No. 154
will have a material impact on the Company's financial statements.

      Critical Accounting Policies

      The Company's consolidated financial statements are prepared in accordance
with accounting principles generally accepted in the United States ("GAAP") and
our significant accounting policies are summarized in Note 1 to the accompanying
consolidated financial statements. The preparation of financial statements in
conformity with GAAP requires management to make estimates and assumptions that
affect reported amounts of assets, liabilities, disclosure of contingent assets
and liabilities at the date of the financial statements and reported amounts of
revenues and expenses during the reporting period. Actual results could differ
significantly from those estimates.

      The Company maintains an allowance for doubtful accounts based on its
historical experience and provides for any specific collection issues that are
identified. Such allowances have historically been adequate to provide for our
doubtful accounts but involve a significant degree of management judgment and
estimation. Worse than expected future economic conditions, unknown customer
credit problems and other factors may require additional allowances for doubtful
accounts to be provided for in future periods. Equipment and software are
recorded at cost. Equipment under capital leases is recorded initially at the
present value of the minimum lease payments. Depreciation and amortization is
calculated primarily using the straight-line method over the estimated useful
lives of the respective assets which range from 3 to 7 years. The internal and
external costs of developing and enhancing software costs related to website
development, other than initial design and other costs incurred during the
preliminary project stage, are capitalized until the software has been
completed. Such capitalized amounts began to be amortized commencing when the
website was placed in service on a straight-line basis over a three-year period.
When assets are sold, retired or otherwise disposed of, the cost and related
accumulated depreciation are eliminated from the accounts and a gain or loss is
recognized. Repair and maintenance costs are expensed as incurred. We evaluate
the realizability of our long-lived assets, including property and equipment,
whenever events or changes in circumstances indicate that the carrying amount of
an asset may not be recoverable. Revenue from sale of products is recognized
upon shipment of products. Revenue from research and development contracts
represents amounts earned pursuant to agreements to perform research and
development activities for third parties and is recognized as earned under the
respective agreement. Because research and development services are provided
evenly over the contract period, revenue is recognized ratably over the contract
period. Research and development agreements in effect in 2004 and 2003 provided
for fees to the Company based on time and materials in exchange for performing
specified research and development functions. Research and development and
advertising costs are expensed when incurred. Inventories are recorded at the
lower of cost or market, using the first-in, first-out method.

Results of Operations


      Three Months Ended September 30, 2005 compared to 2004

      Net sales. Net sales for the quarter ended September 30, 2005 were
approximately $1,635,000, a 25.5% increase from approximately $1,303,000 in the
first quarter of fiscal 2004. North American sales increased 27.8% while sales
to international distributors increased 18.4% from year to year. With respect to
the Company's major product lines, Phospholipids kit sales increased 13.5% for
the quarter, Coagulation kit sales increased 8.8%, HA kit sales increased 56.9%,
whereas Autoimmune kit sales decreased 56.9%. Additionally, OEM sales increased
47.4%. Sales of products manufactured for us by other companies while still
relatively small, are expected to continue to increase during fiscal 2006.

      Cost of sales. Cost of sales, as a percentage of sales, decreased to 35.6%
for the quarter ended September 30, 2005 from 42.8% in 2004 primarily due to
product mix contribution from higher gross margin products.

      Selling and marketing. For the quarter ended September 30, 2005, selling
and marketing expenses increased 1.3% to approximately $381,000 from
approximately $376,000 in 2004. The slight increase was due to increases in
advertising, commissions, royalties and labor-related expenses offset by
decreases in Corgenix UK selling and marketing expenses.

      Research and development. Research and development expenses decreased
17.9% to approximately $129,000 for the quarter ended September 30, 2005 from
approximately $157,000 in 2004. The majority of this decrease involved
reductions in labor-related costs, consulting and purchases and development
costs.

      General and administrative. For the quarter ended September 30, 2005,
general and administrative expenses increased approximately $31,000 or 10.3% to
approximately $330,000 from approximately $299,000 in 2004. This increase was
primarily attributable to increases in labor-related and consulting expenses
partially offset by decreases in merger-related costs.

      Interest expense. Interest expense increased 224.2% to approximately
$338,000 for the quarter ended September 30, 2005 from approximately $104,000 in
2004 due primarily to the amortization of deferred financing costs and discount
on the notes payable to the institutional investors in the recently completed
private placement.

      Liquidity and Capital Resources

      Cash used in operating activities was $152,889 for the current fiscal
quarter compared to cash provided in operating activities of $20,858 during the
prior year's first fiscal quarter. The cash used in operations resulted
primarily from increases in inventories and accounts receivable and decreases in
accounts payable and accrued liabilities. The Company believes that
uncollectible accounts receivable will not have a significant effect on future
liquidity, as a significant portion of its accounts receivable are due from
financially sound enterprises.

      Net cash used by investing activities, the purchase of equipment, was
$16,710 in the quarter compared to $6,528 for the prior year's same quarter. The
increase was mainly attributable to increased spending on refrigeration
equipment and manufacturing equipment.

      Net cash used by financing activities amounted to $6,149 during the recent
quarter compared to $56,388 in the prior fiscal year. This decrease in cash used
versus the comparable prior year was primarily due to lower payments on notes
payable and capital lease obligations .

      Historically, we have financed our operations primarily through long-term
debt and by sales of common and redeemable common stock. We have also financed
operations through sales of diagnostic products and agreements with strategic
partners. Accounts receivable increased 9.2% to $969,458 from $887,645 in 2004
primarily as a result of sales increases during the year.

      Our future capital requirements will depend on a number of factors,
including the ability to complete new equity or debt financing, the possible
redemption of common stock, our profitability or lack thereof, the rate at which
we grow our business and our investment in proprietary research activities, the
ability of our current and future strategic partners to fund outside research
and development activities, our success in increasing sales of both existing and
new products and collaborations, expenses associated with unforeseen litigation,
regulatory changes, competition, technological developments, general economic
conditions and potential future merger and acquisition activity. Our principal
sources of liquidity have been cash raised from the private sale of secured
convertible term notes and the sale of redeemable common and common stock, the
Bridge Note from Genesis, and long-term bank debt financing. The Company
announced in January 2005 the engagement of Ascendiant Securities for investment
banking services. Ascendiant, together with Burnham Securities, arranged the
financing that closed on May 19, 2005, which is described in detail herein. In
connection with this financing, the Company refinanced approximately $1,016,196
of debt, including loans from Vectra Bank, SBA and Genesis Bioventures. We
believe that our current availability of cash, working capital, proceeds from
the issuance of preferred or common stock and debt financing and expected cash
flows from operations resulting from, if necessary, further expense reductions,
will be adequate to meet our ongoing needs for at least the next twelve months.




<page>

                                       Item 3.

                               Controls and Procedures

      Evaluation of disclosure controls and procedures. The Company, under the
supervision and with the participation of the Company's management, including
its Chief Executive Officer and Chief Financial Officer, carried out an
evaluation of the effectiveness of the design and operation of the Company's
disclosure controls and procedures (as defined in Rules 240.13a-14(c) and
15d-14(c) under the Securities Exchange Act of 1934 (the "Exchange Act") as of
the end of the period covered by this quarterly report (the "Evaluation Date").
Based upon this evaluation, the Chief Executive Officer and Chief Financial
Officer concluded that, as of the Evaluation Date, the Company's disclosure
controls and procedures were effective for the purposes of recording,
processing, summarizing and timely reporting information required to be
disclosed by the Company in the reports that it files under the Securities
Exchange Act of 1934 and that such information is accumulated and communicated
to the Company's management in order to allow timely decisions regarding
required disclosure.

      Changes in internal controls. There have been no significant changes in
the Company's internal controls or in other factors that could significantly
affect the Company's disclosure controls and procedures subsequent to the
Evaluation Date, nor were there any significant deficiencies or material
weaknesses in the Company's internal controls.

      Forward-Looking Statements and Risk Factors

      This 10-QSB includes statements that are not purely historical and are
"forward-looking statements" within the meaning of Section 21E of the Securities
Act of 1934, as amended, including statements regarding our expectations,
beliefs, intentions or strategies regarding the future. All statements other
than historical fact contained in this 10-QSB, including, without limitation,
statements regarding future capital requirements, acquisition strategies,
strategic partnership expectations, technological developments, the development,
the availability of necessary components, research and development programs and
distribution plans, are forward-looking statements. All forward-looking
statements included in this 10-QSB are based on information available to us on
the date hereof, and we assume no obligation to update such forward-looking
statements. Although we believe that the assumptions and expectations reflected
in such forward-looking statements are reasonable, we can give no assurance that
such expectations will prove to have been correct or that we will take any
actions that may presently be planned.

      An investment in Corgenix entails certain risks that should be carefully
considered. In addition, these risk factors could cause actual results to differ
materially from those expected include the following:

      We continue to incur losses and are likely to require additional
financing.

      We have incurred operating losses and negative cash flow from operations
for most of our history. Losses incurred since our inception have aggregated
$5,625,252 and there can be no assurance that we will be able to generate
positive cash flows to fund our operations in the future or to pursue our
strategic objectives. Assuming no significant changes from our budget, we
believe that we will have sufficient cash to satisfy our needs for at least the
next twelve months. If we are not able to operate profitably and generate
positive cash flows, we will undoubtedly need to raise additional capital, most
likely via the sale of equity securities, to fund our operations. If we do in
fact need additional financing to meet our requirements, there can be no
assurance that we will be able to obtain such financing on terms satisfactory to
us, if at all. Alternatively, any additional equity financing may be dilutive to
existing stockholders, and debt financing, if available, may include restrictive
covenants. If adequate funds are not available, we might be required to limit
our research and development activities or our selling, marketing and
administrative activities any of which could have a material adverse effect on
the future of the business.

      We depend upon collaborative relationships and third parties for product
      development and commercialization.

      We have historically entered into research and development agreements with
collaborative partners, from which we derived revenues in past years. Pursuant
to these agreements, our collaborative partners have specific responsibilities
for the costs of development, promotion, regulatory approval and/or sale of our
products. We will continue to rely on future collaborative partners for the
development of products and technologies. There can be no assurance that we will
be able to negotiate such collaborative arrangements on acceptable terms, if at
all, or that current or future collaborative arrangements will be successful. To
the extent that we are not able to establish such arrangements, we could be
forced to undertake such activities entirely at our own expense. The amount and
timing of resources that any of these partners devotes to these activities may
be based on progress by us in our product development efforts. Collaborative
arrangements may be terminated by the partner upon prior notice without cause
and there can be no assurance that any of these partners will perform its
contractual obligations or that it will not terminate its agreement. With
respect to any products manufactured by third parties, there can be no assurance
that any third-party manufacturer will perform acceptably or that failures by
third parties will not delay clinical trials or the submission of products for
regulatory approval or impair our ability to deliver products on a timely basis.

      There can be no assurance of successful or timely development of
additional products.

      Our business strategy includes the development of additional diagnostic
products for the diagnostic business. Our success in developing new products
will depend on our ability to achieve scientific and technological advances and
to translate these advances into commercially competitive products on a timely
basis. Development of new products requires significant research, development
and testing efforts. We have limited resources to devote to the development of
products and, consequently, a delay in the development of one product or the use
of resources for product development efforts that prove unsuccessful may delay
or jeopardize the development of other products. Any delay in the development,
introduction and marketing of future products could result in such products
being marketed at a time when their cost and performance characteristics would
not enable them to compete effectively in their respective markets. If we are
unable, for technological or other reasons, to complete the development and
introduction of any new product or if any new product is not approved or cleared
for marketing or does not achieve a significant level of market acceptance, our
ability to remain competitive in our product niches would be impaired.
<page>

      Competition in the human medical diagnostics industry is, and is expected
      to remain, significant.

      Our competitors range from development stage diagnostics companies to
major domestic and international pharmaceutical and biotechnology companies.
Many of these companies have financial, technical, marketing, sales,
manufacturing, distribution and other resources significantly greater than ours.
In addition, many of these companies have name recognition, established
positions in the market and long standing relationships with customers and
distributors also greater than ours. Moreover, the diagnostics industry
continues to demonstrate a degree consolidation, whereby some of the large
domestic and international pharmaceutical companies have been acquiring
mid-sized diagnostics companies, further increasing the concentration of
resources. There can be no assurance that technologies will not be introduced
that could be directly competitive with or superior to our technologies.

      Our products and activities are subject to regulation by various
      governments and government agencies.

      The testing, manufacture and sale of our products is subject to regulation
by numerous governmental authorities, principally the United States Food and
Drug Administration and certain foreign regulatory agencies. Pursuant to the
Federal Food, Drug, and Cosmetic Act, and the regulations promulgated there
under, the FDA regulates the preclinical and clinical testing, manufacture,
labeling, distribution and promotion of medical devices. We are limited in our
ability to commence marketing or commercial sales in the United States of new
products under development until we receive clearance or approval from the FDA.
The testing for, preparation of and subsequent FDA regulatory review of required
filings can be a lengthy, expensive and uncertain process. Noncompliance with
applicable requirements can result in, among other consequences, fines,
injunctions, civil penalties, recall or seizure of products, repair, replacement
or refund of the cost of products, total or partial suspension of production,
failure of the government to grant pre-market clearance or pre-market approval
for devices, withdrawal of marketing clearances or approvals, and criminal
prosecution.

      There can be no assurance that we will be able to obtain necessary
regulatory approvals or clearances for our products on a timely basis, if at
all, and delays in receipt of or failure to receive such approvals or
clearances, the loss of previously received approvals or clearances, limitations
on intended use imposed as a condition of such approvals or clearances or
failure to comply with existing or future regulatory requirements could
negatively impact our sales and thus have a material adverse effect on our
business.

      As a manufacturer of medical devices for marketing in the United States,
we are required to adhere to applicable regulations setting forth detailed good
manufacturing practice requirements, which include testing, control and
documentation requirements. We must also comply with Medical Device Report (MDR)
requirements, which require that a manufacturer reports to the FDA any incident
in which its product may have caused or contributed to a death or serious
injury, or in which its product malfunctioned and, if the malfunction were to
recur, it would be likely to cause or contribute to a death or serious injury.
We are also subject to routine inspection by the FDA for compliance with QSR
requirements, MDR requirements and other applicable regulations. Labeling and
promotional activities are subject to scrutiny by the FDA and, in certain
circumstances, by the Federal Trade Commission. We may incur significant costs
to comply with laws and regulations in the future, which would decrease our net
income or increase our net loss and thus have a potentially material adverse
effect upon our business, financial conditions and results of operations.

      Distribution of diagnostic products outside the United States is subject
to extensive foreign government regulation. These regulations, including the
requirements for approvals or clearance to market, the time required for
regulatory review and the sanctions imposed for violations, vary from country to
country. We may be required to incur significant costs in obtaining or
maintaining foreign regulatory approvals. In addition, the export of certain of
our products that have not yet been cleared for United States commercial
distribution may be subject to FDA export restrictions. Failure to obtain
necessary regulatory approval or the failure to comply with regulatory
requirements could reduce our product sales and thus have a potentially material
adverse effect on our business, financial condition and results of operations.

      We depend upon distribution partners for sales of diagnostic products in
international markets.

      We have entered into distribution agreements with collaborative partners
in which we have granted distribution rights for certain of our products to
these partners within specific international geographic areas. Pursuant to these
agreements, our collaborative partners have certain responsibilities for market
development, promotion, and sales of the products. If any of these partners
fails to perform its contractual obligations or terminates its agreement, this
could have a reduce our sales and cash flow and thus have a potentially material
adverse effect on our business, financial condition and results of operations.
<page>

      Third party reimbursement for purchases of our diagnostic products is
      uncertain.

      In the United States, health care providers that purchase diagnostic
products, such as hospitals and physicians, generally rely on third party
payers, principally private health insurance plans, federal Medicare and state
Medicaid, to reimburse all or part of the cost of the purchase. Third party
payers are increasingly scrutinizing and challenging the prices charged for
medical products and services and they can affect the pricing or the relative
attractiveness of the product. Decreases in reimbursement amounts for tests
performed using our diagnostic products, failure by physicians and other users
to obtain reimbursement from third party payers, or changes in government and
private third party payers' policies regarding reimbursement of tests utilizing
diagnostic products, may affect our ability to sell our diagnostic products
profitably. Market acceptance of our products in international markets is also
dependent, in part, upon the availability of reimbursement within prevailing
health care payment systems.

      Our success depends, in part, on our ability to obtain patents and license
      patent rights, to maintain trade secret protection and to operate without
      infringing on the proprietary rights of others.

      There can be no assurance that our issued patent will afford meaningful
protection against a competitor, or that patents issued or licensed to us will
not be infringed upon or designed around by others, or that others will not
obtain patents that we would need to license or design around. We could incur
substantial costs in defending the Company or our licensees in litigation
brought by others. The potential for reduced sales and increased legal expenses
would have a negative impact on our cash flow and thus our overall business
could be adversely affected.

      We may not be able to successfully implement our plans to acquire other
      companies or technologies.

      Our growth strategy includes the acquisition of complementary companies,
products or technologies. There is no assurance that we will be able to identify
appropriate companies or technologies to be acquired, to negotiate satisfactory
terms for such an acquisition, or to obtain sufficient capital to make such
acquisitions. Moreover, because of limited cash resources, we will be unable to
acquire any significant companies or technologies for cash and our ability to
effect acquisitions in exchange for our capital stock may depend upon the market
prices for our common stock, which could result in significant dilution to its
existing stockholders. If we do complete one or more acquisitions, a number of
risks arise, such as disruption of our existing business, short-term negative
effects on our reported operating results, diversion of management's attention,
unanticipated problems or legal liabilities, and difficulties in the integration
of potentially dissimilar operations. Any of these factors could materially harm
Corgenix's business or its operating results.

      We depend on suppliers for our products' components.

      The components of our products include chemical, biological and packaging
supplies that are generally available from several suppliers, except certain
antibodies and other critical components, which we purchase from single
suppliers. We mitigate the risk of a loss of supply by maintaining a sufficient
supply of such antibodies to ensure an uninterrupted supply for at least three
months. We have also qualified second vendors for all critical raw materials and
believe that we can substitute a new supplier with respect to any of these
components in a timely manner. If, for some reason, we lose our main supplier
for a given material, there can be no assurances that we will be able to
substitute a new supplier in a timely manner and failure to do so could impair
the manufacturing of certain of our products and thus have a material adverse
effect on our business, financial condition and results of operations.

      We have only limited manufacturing experience with certain products.

      Although we have manufactured over twelve million diagnostic tests based
on our proprietary applications of ELISA (enzyme linked immuno-absorbent assay)
technology, certain of our diagnostic products in consideration for future
development, incorporate technologies with which we have limited manufacturing
experience. Assuming successful development and receipt of required regulatory
approvals, significant work may be required to scale up production for each new
product prior to such product's commercialization. There can be no assurance
that such work can be completed in a timely manner and that such new products
can be manufactured cost-effectively, to regulatory standards or in sufficient
volume.

      Due to the specialized nature of our business, our success will be highly
      dependent upon our ability to attract and retain qualified scientific and
      executive personnel.

      We believe our success will depend to a significant extent on the efforts
and abilities of Dr. Luis R. Lopez and Douglass T. Simpson, who would be
difficult to replace. There can be no assurance that we will be successful in
attracting and retaining such skilled personnel, who are generally in high
demand by other companies. The loss of, inability to attract, or poor
performance by key scientific and executive personnel may have a material
adverse effect on our business, financial condition and results of operations.
<page>
      The testing, manufacturing and marketing of medical diagnostic devices
      entails an inherent risk of product liability claims.

      To date, we have experienced no product liability claims, but any such
claims arising in the future could have a material adverse effect on our
business, financial condition and results of operations. Potential product
liability claims may exceed the amount of our insurance coverage or may be
excluded from coverage under the terms of our policy or limited by other claims
under our umbrella insurance policy. Additionally, there can be no assurance
that our existing insurance can be renewed by us at a cost and level of coverage
comparable to that presently in effect, if at all. In the event that we are held
liable for a claim against which we are not insured or for damages exceeding the
limits of our insurance coverage, such claim could have a material adverse
effect on our cash flow and thus potentially a materially adverse effect on our
business, financial condition and results of operations.

      There has, to date, been no active public market for our Common Stock, and
      there can be no assurance that an active public market will develop or be
      sustained.

      Although our Common Stock has been traded on the OTC Bulletin Board(R)
since February 1998, the trading has been sporadic with insignificant volume.

      Moreover, the over-the-counter markets for securities of very small
companies historically have experienced extreme price and volume fluctuations.
These broad market fluctuations and other factors, such as new product
developments, trends in our industry, the investment markets, economic
conditions generally, and quarterly variation in our results of operations, may
adversely affect the market price of our common stock. In addition, our common
stock is subject to rules adopted by the Securities and Exchange Commission
regulating broker-dealer practices in connection with transactions in "penny
stocks." Such rules require the delivery prior to any penny stock transaction of
a disclosure schedule explaining the penny stock market and all associated risks
and impose various sales practice requirements on broker-dealers who sell penny
stocks to persons other than established customers and accredited investors,
which are generally defined as institutions or an investor with a net worth in
excess of $1,000,000 or annual income exceeding $200,000 or $300,000 together
with the spouse. For these types of transactions the broker-dealer must make a
special suitability determination for the purchaser and have received the
purchaser's written consent to the transaction prior to sale. The additional
burdens imposed upon broker-dealers by such requirements may discourage
broker-dealers from effecting transactions in securities subject to the penny
stock rules.

      There are risks associated with fluctuating exchange rates.

      Our financial statements are presented in US dollars. At the end of each
fiscal quarter and the fiscal year, we convert the financial statements of
Corgenix UK, which operates in pounds sterling, into US dollars, and consolidate
them with results from Corgenix, Inc. We may, from time to time, also need to
exchange currency from income generated by Corgenix UK. Foreign exchange rates
are volatile and can change in an unknown and unpredictable fashion. Should the
foreign exchange rates change to levels different than anticipated by us, our
business, financial condition and results of operations may be adversely
affected.

<page>






                          CORGENIX MEDICAL CORPORATION


                                     PART II


                                Other Information


Item 1.    Legal Proceedings


       None.


Item 2.    Changes in Securities and Use of Proceeds


      None

Item 3.    Defaults Upon Senior Securities


      None


Item 4.    Submission of Matters to a Vote of Security Holders


      None


Item 5.    Other Information


      None

Item 6.  Exhibits and Reports on Form 8-K.

a. Index to and Description of Exhibits.


Exhibit
Number   Description of Exhibit

                           1.1 Underwriting Agreement
                        2.1 Plan of purchase, sale, etc.
3.1      Articles of Incorporation, as amended, filed with the Company's
         Registration Statement on Form 10-SB filed June 29, 1998, and
         incorporated herein by reference.

3.2      Bylaws, filed with the Company's Registration Statement on Form 10-SB
         filed June 29, 1998, and incorporated herein by reference.

4.1      Form of Term Note Security Agreement dated May 19, 2005, filed with the
         Company's Form 8-K filed May 26, 2005, and incorporated herein by
         reference.
4.2      Form of Common Stock Purchase Warrant dated May 19, 2005, filed with
         the Company's Form 8-K filed May 26, 2005, and incorporated herein by
         reference.
10.4     License Agreement dated June 30, 2001 between Chugai
         Diagnostic Science Co., Ltd. and Corgenix Medical
         Corporation, filed with the Company's June 30, 2001 Form
         10-KSB, and incorporated herein by reference.

10.5     Office Lease dated May 5, 2001 between Crossroads West LLC/Decook
         Metrotech LLC and Corgenix, Inc., filed with the Company's June 30,
         2001 Form-10KSB, and incorporated herein by reference.
10.6     Guarantee dated November 1, 1997 between William George Fleming,
         Douglass Simpson and Geoffrey Vernon Callen, filed with the Company's
         Registration Statement on Form 10-SB filed June 29, 1998, and
         incorporated herein by reference.
10.7     Employment Agreement dated July 1, 2005 between Luis R. Lopez and the
         Company filed with the Company's June 30, 2005 Form 10-KSB and
         incorporated herein by reference.

10.8     Employment Agreement dated July 1, 2005 between Douglass T. Simpson and
         the Company filed with the Company's June 30, 2005 Form-10KSB, and
         incorporated herein by reference.
10.9     Employment Agreement dated July 1, 2005 between William H. Critchfield
         and the Company filed with the Company's June 30, 2005Form-10KSB, and
         incorporated herein by reference.
10.10    Employment Agreement dated July 1, 2005 between Ann L. Steinbarger and
         the Company filed with the Company's June 30, 2005Form-10KSB, and
         incorporated herein by reference.
10.11    Employment Agreement dated July 1, 2005 between Taryn G. Reynolds and
         the Company filed with the Company's June 30, 2005Form-10KSB, and
         incorporated herein by reference.
10.14    Note dated January 6, 1997 between REAADS Medical Products, Inc. and
         Eagle Bank, filed with the Company's Registration Statement on Form
         10-SB filed June 29, 1998, and incorporated herein by reference.
10.15    Form of Indemnification Agreement between the Company and its directors
         and officers, filed with the Company's Registration Statement on Form
         10-SB/A-1 filed September 24, 1998 and incorporated herein by
         reference.
10.16    Warrant agreement dated June 1, 2000 between the Company and Taryn G.
         Reynolds, filed with the Company's June 30, 2001 Form 10-KSB, and
         incorporated herein by reference.
10.19    Consulting Agreement dated September 29, 2002 between Eiji Matsuura,
         Ph.D and the Company, filed with the Company's September 30, 2002 Form
         10-QSB, and incorporated herein by reference.
10.20    License Agreement dated September 29, 2002 between Eiji Matsuura, Ph.D
         and the Company, filed with the Company's June 30, 2002 Form 10-QSB,
         and incorporated herein by reference.
10.23    Amended and Restated 1999 Incentive Stock Plan filed with the Company's
         November 2002 filing of Proxy Statement Schedule 14A Information, and
         incorporated herein by reference.
10.24    Amended and Restated Employee Stock Purchase Plan, filed with the
         Company's November 2002 filing of Proxy Statement Schedule 14A
         Information, and incorporated herein by reference.
10.25    Agreement and Plan of Merger dated as of March 12, 2004 by
         and among Genesis Bioventures, Inc., GBI Acquisition
         Corporation and Corgenix Medical Corp., filed with the
         Company's March 31, 2004 Form 10-QSB, and incorporated
         herein by reference.
10.26    Product Development, Manufacturing and Distribution Agreement dated May
         13, 2004 between Creative Clinical Concepts, Inc. and the Company,
         filed with the Company's June 30, 2005 Form 10-KSB, and incorporated
         herein by reference.
10.28    Warrant Agreement dated October 11, 2001, between Phillips V. Bradford
         and the Company, filed with the Company's December 31, 2001Form 10-QSB,
         and incorporated herein by reference.
10.29    Warrant Agreement dated October 11, 2001 between Charles F. Ferris and
         the Company, filed with the Company's December 31, 2001 Form 10-QSB,
         and incorporated herein by reference.
10.30    Underlease Agreement dated October 3, 2001 between G.V. Calen, A.G.
         Pirmohamed and Corgenix UK, Ltd,. filed with the Company's December 31,
         2001 Form 10-QSB, and incorporated herein by reference.
10.31    Supply Agreement dated September 12, 2003 between DiaDexus, Inc. and
         the Company filed with the Company's June 30, 2005 Form-10KSB, and
         incorporated herein by reference.
10.32    Distribution Agreement and OEM Agreement dated March 14, 2002 between
         RhiGene, Inc., and the Company, filed with the Company's March 31, 2002
         Form 10-QSB, and incorporated herein by reference.
10.33    Distribution Agreement and OEM Supply Agreement dated March 31, 2005
         between MBL International, Inc. and the Company filed with the
         Company's June 30, 2005 Form-10KSB, and incorporated herein by
         reference.
10.34    Form of Securities Purchase Agreement dated May 19, 2005 filed with the
         Company's Form 8-K filed May 26, 2005, and incorporated herein by
         reference.
10.35    Form of Secured Convertible Term Note dated May 19, 2005 filed with the
         Company's Form 8-K filed May 26, 2005, and incorporated herein by
         reference.
10.36    Form of Registration Rights Agreement dated May 19, 2005 filed with the
         Company's Form 8-K filed May 26, 2005, and incorporated herein by
         reference.
10.37    Form of Restricted Account Agreement dated May 19, 2005 filed with the
         Company's Form 8-K filed May 26, 2005, and incorporated herein by
         reference.
10.38    Form of Restricted Account Side Letter dated May 19, 2005 filed with
         the Company's Form 8-K filed May 26, 2005, and incorporated herein by
         reference.
10.39    Form of Stock Pledge Agreement dated May 19, 2005 filed with the
         Company's Form 8-K filed May 26, 2005, and incorporated herein by
         reference.
10.40    Form of Lockup Letter dated May 19, 2005 filed with the Company's Form
         8-K filed May 26, 2005, and incorporated herein by reference.
10.41    Form of Subsidiary Guaranty dated May 19, 2005 filed with the Company's
         Form 8-K filed May 26, 2005, and incorporated herein by reference.
10.42    2005 Incentive Compensation Plan dated April 21, 2005 filed with the
         Company's June 30, 2005 Form-10KSB, and incorporated herein by
         reference.
10.43    Note dated August 1, 2005 between the Company and Medical
         & Biological Laboratories, Co., Ltd., filed with the
         Company's June 30, 2005 Form-10KSB, and incorporated
         herein by reference.
10.44    Amendment to Common Stock Purchase Agreement and Common
         Stock Purchase Warrant dated August 1, 2005 between the
         Company and Medical & Biological Laboratories, Co., Ltd.,
         filed with the Company's June 30, 2005 Form-10KSB, and
         incorporated herein by reference.
21.1     Subsidiaries of the Registrant, filed as Exhibit 21.1 to the Company's
         Registration Statement on Form 10-SB, filed June 29, 1998.
31.1*    Certification of Chief Executive Officer pursuant to
         section 302 of the Sarbanes-Oxley Act.
31.2*    Certification of Chief  Financial Officer pursuant to
         section 302 of the Sarbanes-Oxley Act..
32.1*    Certification by Chief Executive Officer and Chief Financial Officer
         pursuant to 18 U.S.C. Section 1350, or adopted pursuant to Section 906
         of the Sarbanes-Oxley Act of 2002.
*  Filed herewith.
---------------------------------------
      (b)  Reports on Form 8-K.

1.           Form 8-K filed September 23, 2005 Results of Operation and
             Financial Condition.
2.           Form 8-K filed September 30, 2005 Departure of Directors or
             Principal Officers; Election of Directors; Appointment of Principal
             Officers
<page>

                                                                    Exhibit 31.1

                                  CERTIFICATION

I, Douglass T. Simpson, President and Chief Executive Officer, certify that:

1.         I have reviewed this quarterly report on Form 10-QSB of Corgenix
           Medical Corporation.

2.         Based on my knowledge, this quarterly report does not contain any
           untrue statement of a material fact or omit to state a material fact
           necessary to make the statements made, in light of the circumstances
           under which such statements were made, not misleading with respect to
           the period covered by this quarterly report.

3.         Based on my knowledge, the financial statements, and other financial
           information included in this report, fairly present in all material
           respects the financial condition, results of operations and cash
           flows of the registrant as of, and for, the periods presented in this
           quarterly report;

4.         The small business issuer's other certifying officers and I are
           responsible for establishing and maintaining disclosure controls and
           procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
           and internal control over financial reporting (as defined in Exchange
           Act Rules 13a-15(f) and 15d-15(f)) for the small business issuer and
           have:

(a)        Designed such disclosure controls and procedures, or caused such
           disclosure controls and procedures to be designed under our
           supervision, to ensure that material information relating to the
           small business issuer, including its consolidated subsidiaries, is
           made known to us by others within those entities, particularly during
           the period in which this report is being prepared;
(b)        Evaluated the effectiveness of the small business issuer's disclosure
           controls and procedures and presented in this report our conclusions
           about the effectiveness of the disclosure controls and procedures, as
           of the end of the period covered by this report based on such
           evaluation; and
(c)        Disclosed in this report any change in the small business issuer's
           internal control over financial reporting that occurred during the
           small business issuer's most recent fiscal quarter (the small
           business issuer's fourth fiscal quarter in the case of a quarterly
           report) that has materially affected, or is reasonably likely to
           materially affect, the small business issuer's internal control over
           financial reporting; and

5.         The small business issuer's other certifying officers and I have
           disclosed, based on our most recent evaluation of internal control
           over financial reporting, to the small business issuer's auditors and
           the audit committee of registrant's board of directors:

(a)        All significant deficiencies in the design or operation of internal
           control over financial reporting which are reasonably likely to
           adversely affect the small business issuer's ability to record,
           process, summarize and report financial information; and
(b)        Any fraud, whether or not material, that involves management or other
           employees who have a significant role in the small business issuer's
           internal control over financial reporting.


   Date:  November 10, 2005

       /S/Douglass T. Simpson
       President and Chief Executive Officer


<PAGE>




                                                                    Exhibit 31.2
                                  CERTIFICATION


I, William H. Critchfield, Senior Vice President and Chief Financial Officer
certify that:

1.         I have reviewed this quartely report on Form 10-QSB of Corgenix
           Medical Corporation.

2.         Based on my knowledge, this quarterly report does not contain any
           untrue statement of a material fact or omit to state a material fact
           necessary to make the statements made, in light of the circumstances
           under which such statements were made, not misleading with respect to
           the period covered by this quarterly report.

3.         Based on my knowledge, the financial statements, and other financial
           information included in this report, fairly present in all material
           respects the financial condition, results of operations and cash
           flows of the registrant as of, and for, the periods presented in this
           quarterly report;

4.         The small business issuer's other certifying officers and I are
           responsible for establishing and maintaining disclosure controls and
           procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
           and internal control over financial reporting (as defined in Exchange
           Act Rules 13a-15(f) and 15d-15(f)) for the small business issuer and
           have:

a.         Designed such disclosure controls and procedures, or caused such
           disclosure controls and procedures to be designed under our
           supervision, to ensure that material information relating to the
           small business issuer, including its consolidated subsidiaries, is
           made known to us by others within those entities, particularly during
           the period in which this report is being prepared;
b.         Evaluated the effectiveness of the small business issuer's disclosure
           controls and procedures and presented in this report our conclusions
           about the effectiveness of the disclosure controls and procedures, as
           of the end of the period covered by this report based on such
           evaluation; and
c.         Disclosed in this report any change in the small business issuer's
           internal control over financial reporting that occurred during the
           small business issuer's most recent fiscal quarter (the small
           business issuer's fourth fiscal quarter in the case of a quarterly
           report) that has materially affected, or is reasonably likely to
           materially affect, the small business issuer's internal control over
           financial reporting; and

5.         The small business issuer's other certifying officers and I have
           disclosed, based on our most recent evaluation of internal control
           over financial reporting, to the small business issuer's auditors and
           the audit committee of registrant's board of directors:

a.         All significant deficiencies in the design or operation of internal
           control over financial reporting which are reasonably likely to
           adversely affect the small business issuer's ability to record,
           process, summarize and report financial information; and
b.         Any fraud, whether or not material, that involves management or other
           employees who have a significant role in the small business issuer's
           internal control over financial reporting.


   Date:  November 10, 2005
       /S/William H. Critchfield
       Senior Vice President and Chief Financial Officer


<PAGE>






                                                                   Exhibit 32.1

                                  CERTIFICATION
            PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
        SUBSECTIONS (a) AND (b) OF SECTION 1350, CHAPTER 63 OF TITLE 18,
                               UNITED STATES CODE

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and
(b) of section 1350, chapter 63 of Title 18, United States Code), the
undersigned officers of Corgenix Medical Corporation, a Nevada corporation (the
"Company"), does hereby certify with respect to the Quartely Report of the
Company on Form 10-QSB for the quarter ended September 30, 2005 as filed with
the Securities an Exchange Commission (the "10-QSB Report") that:

i.              the 10-QSB Report fully complies with the requirements of
                section 13(a) or 15(d) of the Securities Exchange Act of 1934;
                and

ii.             the information contained in the 10-QSB Report fairly presents,
                in all material respects, the financial condition and results of
                operations of the Company.


           Dated:    November 10, 2005

      This Certification is made solely for purposes of 18 U.S.C. Section 1350,
      subject to the knowledge standard contained therein, and not for any other
      purpose.

      A signed original of this written statement required by Section 906 of the
      Sarbanes-Oxley Act has been provided to the Company and will be retained
      by the Company and furnished to the Securities and Exchange Commission or
      its staff upon request. This written statement shall not be deemed to be
      "filed" as part of the quarterly report on Form 10-QSB that it
      accompanies.

/S/Douglass T. Simpson
President and Chief Executive Officer


/S/William H. Critchfield
Senior Vice President and Chief Financial Officer


<page>

                                   SIGNATURES


      In accordance with the requirements of the Securities Exchange Act of
1934, the registrant caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.



                                    CORGENIX MEDICAL CORPORATION



November 10, 2005                 By:   /s/ Douglass T. Simpson
                                  -----------------------------
                                  Douglass T. Simpson
                                  President and Chief Executive Officer